Suggested remit: To appraise the clinical and cost effectiveness of serplulimab with carboplatin and etoposide within its marketing authorisation for untreated extensive-stage small-cell lung cancer.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6346

Project Team

Project lead Kate Moore

Email enquiries

External Assessment Group Newcastle NIHR TAR Team, Newcastle University

Timeline

Key events during the development of the guidance:

Date Update
12 September 2024 - 10 October 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6346
12 September 2024 In progress. Scoping commenced.
05 September 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual